Pharmacological Treatment of Patients with Mild to Moderate COVID-19: A Comprehensive Review

Reinaldo B. Bestetti, Rosemary Furlan-Daniel and Vinicius M. R. Silva
Additional contact information
Reinaldo B. Bestetti: Department of Medicine, University of Ribeirão Preto, 2201 Costabile Romano, Ribeirão Preto 14096-385, Brazil
Rosemary Furlan-Daniel: Department of Medicine, University of Ribeirão Preto, 2201 Costabile Romano, Ribeirão Preto 14096-385, Brazil
Vinicius M. R. Silva: Department of Medicine, University of Ribeirão Preto, 2201 Costabile Romano, Ribeirão Preto 14096-385, Brazil

IJERPH, 2021, vol. 18, issue 13, 1-12

Abstract: Mild to moderate COVID-19 can be found in about 80% of patients. Although mortality is low, mild to moderate COVID-19 may progress to severe or even critical stages in about one week. This poses a substantial burden on the health care system, and ultimately culminates in death or incapacitation and hospitalization. Therefore, pharmacological treatment is paramount for patients with this condition, especially those with recognized risk factors to disease progression. We conducted a comprehensive review in the medical literature searching for randomized studies carried out in patients with mild to moderate COVID-19. A total of 14 randomized studies were identified, enrolling a total of 6848 patients. Nine studies (64%) were randomized, placebo-controlled trials, whereas five were open-label randomized trials (35%). We observed that Bamlanivimab and nitazoxanide reduced viral load, whereas ivermectin may have shortened time to viral clearance; Interferon Beta-1 reduced time to viral clearance and vitamin D reduced viral load; Favirapir, peginterferon, and levamisole improved clinical symptoms, whereas fluvoxamine halted disease progression; inhaled budesonide reduced the number of hospitalizations and visits to emergency departments; colchicine reduced the number of deaths and hospitalizations. Collectively, therefore, these findings show that treatment of early COVID-19 may be associated with reduced viral load, thus potentially decreasing disease spread in the community. Moreover, treatment of patients with mild to moderate COVID-19 may also be associated with improved clinical symptoms, hospitalization, and disease progression. We suggest that colchicine, inhaled budesonide, and nitazoxanide, along with nonpharmacological measures, based on efficacy and costs, may be used to mitigate the effects of the COVID-19 pandemic in middle-income countries.

Keywords: COVID-19; SARS-CoV-2; mild disease; moderate disease (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/13/7212/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/13/7212/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:13:p:7212-:d:589079

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().